Encapsulation of Acetylshikonin by Polyamidoamine Dendrimers for Preparing Prominent Nanoparticles

Overview

Journal AAPS PharmSciTech

Publisher Springer

Specialty Pharmacology

Date 2014 Jan 23

PMID 24449188

Citations 2

Authors

Jianqing Peng

Wen Zhou

Xinyi Xia

Xiaole Qi

Luan Sun

Min Wang

Zhenghong Wu

Zhengrong Li

Affiliations

Soon will be listed here.

Abstract

Acetylshikonin (AS) has demonstrated antitumor potential. However, the development of therapeutic applications utilizing AS is inhibited by its poor solubility in water. In the present work, polyamidoamine (PAMAM) dendrimers and their PEGylated derivatives were employed to increase the solubility of AS. A distinct color transition was observed during the encapsulation of AS suggesting strong intermolecular forces between PAMAM and AS. Ultraviolet-visible, high-performance liquid chromatography, and (1)H NMR were used to verify the interaction between PAMAM and AS. The maximum amount of combined AS to each PAMAM molecule was determined. The cytotoxicity of AS nanoparticles was evaluated against leukemia (K562) and breast cancer (SK-BR-3) cell lines; the AS nanoparticles were shown to effectively inhibit tumor cells.

Citing Articles

Poly(amidoamine) Dendrimer/Camptothecin Complex: From Synthesis to In Vitro Cancer Cell Line Studies.

Oledzka E, Pasnik K, Domanska I, Zielinska-Pisklak M, Piotrowska U, Sobczak M Molecules. 2023; 28(6).

PMID: 36985668 PMC: 10052527. DOI: 10.3390/molecules28062696.

Pharmacology, toxicity and pharmacokinetics of acetylshikonin: a review.

Zhang Z, Bai J, Zeng Y, Cai M, Yao Y, Wu H Pharm Biol. 2020; 58(1):950-958.

PMID: 32956595 PMC: 7534356. DOI: 10.1080/13880209.2020.1818793.

References

Utreja S, Khopade A, Jain N . Lipoprotein-mimicking biovectorized systems for methotrexate delivery. Pharm Acta Helv. 1999; 73(6):275-9. DOI: 10.1016/s0031-6865(99)00002-3. View

Yiyun C, Tongwen X . Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur J Med Chem. 2005; 40(11):1188-92. DOI: 10.1016/j.ejmech.2005.06.010. View

Rajasekar S, Park D, Park C, Park S, Park Y, Kim S . In vitro and in vivo anticancer effects of Lithospermum erythrorhizon extract on B16F10 murine melanoma. J Ethnopharmacol. 2012; 144(2):335-45. DOI: 10.1016/j.jep.2012.09.017. View

Gupta U, Agashe H, Asthana A, Jain N . Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules. 2006; 7(3):649-58. DOI: 10.1021/bm050802s. View

Kontogiannopoulos K, Assimopoulou A, Hatziantoniou S, Karatasos K, Demetzos C, Papageorgiou V . Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology. Int J Pharm. 2011; 422(1-2):381-9. DOI: 10.1016/j.ijpharm.2011.09.031. View

Sankawa U, Ebizuka Y, Miyazaki T, Isomura Y, Otsuka H . Antitumor activity of shikonin and its derivatives. Chem Pharm Bull (Tokyo). 1977; 25(9):2392-5. DOI: 10.1248/cpb.25.2392. View

Bhadra D, Bhadra S, Jain S, Jain N . A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003; 257(1-2):111-24. DOI: 10.1016/s0378-5173(03)00132-7. View

Maingi V, Venkata Satish Kumar M, Maiti P . PAMAM dendrimer-drug interactions: effect of pH on the binding and release pattern. J Phys Chem B. 2012; 116(14):4370-6. DOI: 10.1021/jp211515g. View

Malam Y, Loizidou M, Seifalian A . Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30(11):592-9. DOI: 10.1016/j.tips.2009.08.004. View

10.

Lee H, Lee H, Magesh V, Nam D, Lee E, Ahn K . Shikonin, acetylshikonin, and isobutyroylshikonin inhibit VEGF-induced angiogenesis and suppress tumor growth in lewis lung carcinoma-bearing mice. Yakugaku Zasshi. 2008; 128(11):1681-8. DOI: 10.1248/yakushi.128.1681. View

11.

Svenson S, Tomalia D . Dendrimers in biomedical applications--reflections on the field. Adv Drug Deliv Rev. 2005; 57(15):2106-29. DOI: 10.1016/j.addr.2005.09.018. View

12.

Majoros I, Myc A, Thomas T, Mehta C, Baker Jr J . PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules. 2006; 7(2):572-9. DOI: 10.1021/bm0506142. View

13.

Zhao L, Wu Q, Cheng Y, Zhang J, Wu J, Xu T . High-throughput screening of dendrimer-binding drugs. J Am Chem Soc. 2010; 132(38):13182-4. DOI: 10.1021/ja106128u. View

14.

Chang Y, Kuo S, Weng S, Jan S, Ko F, Teng C . Inhibition of platelet aggregation by shikonin derivatives isolated from Arnebia euchroma. Planta Med. 1993; 59(5):401-4. DOI: 10.1055/s-2006-959718. View

15.

DEmanuele A, Attwood D . Dendrimer-drug interactions. Adv Drug Deliv Rev. 2005; 57(15):2147-62. DOI: 10.1016/j.addr.2005.09.012. View

16.

Staniforth V, Wang S, Shyur L, Yang N . Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo. J Biol Chem. 2003; 279(7):5877-85. DOI: 10.1074/jbc.M309185200. View

17.

Papageorgiou V . Naturally occurring isohexenylnaphthazarin pigments: a new class of drugs. Planta Med. 1980; 38(3):193-203. DOI: 10.1055/s-2008-1074864. View

18.

Gullotti E, Yeo Y . Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009; 6(4):1041-51. PMC: 2743941. DOI: 10.1021/mp900090z. View

19.

Jiang Y, Tang G, Zhang L, Kong S, Zhu S, Pei Y . PEGylated PAMAM dendrimers as a potential drug delivery carrier: in vitro and in vivo comparative evaluation of covalently conjugated drug and noncovalent drug inclusion complex. J Drug Target. 2010; 18(5):389-403. DOI: 10.3109/10611860903494203. View

20.

Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener J . Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release. 2000; 65(1-2):133-48. DOI: 10.1016/s0168-3659(99)00246-1. View